Explore the Agenda
8:00 am Morning Refreshments
8:50 am Chair’s Opening Remarks
Designing Mash Combination Therapies To Target Multiple Disease Drivers, Enable Synergy & Deliver Superior Clinical Outcomes
9:00 am Adapting Mash Development Strategies Within An Evolving Treatment Landscape To Define Clinical Value, Enable Differentiation & Establish Future Standards Of Care
- Navigating the transition to a post-approval MASH landscape to address emerging clinical expectations and unmet patient needs, enabling more effective development planning and strengthening future therapeutic value
- Evaluating how emerging therapies, active comparators and future combination approaches will shape post-approval development pathways, enabling clearer differentiation and improving treatment integration strategies
- Designing late-stage clinical and registrational strategies around evolving standards of care to improve regulatory readiness, accelerating broader adoption and long-term patient impact
9:30 am Advancing Genetically Validated Targets & Combination Development Strategies to Improve Therapeutic Precision, Enable Differentiation & Support Long-Term Success in MASH
- Leveraging insights from genetically validated disease drivers to identify high confidence therapeutic targets, enabling more informed development strategies and improving the likelihood of clinical success
- Evaluating how emerging targets associated with metabolic dysfunction and fibrotic progression may complement existing therapeutic approaches, strengthening differentiation opportunities and expanding future treatment potential
- Exploring how genetically informed therapies could be incorporated into combination development strategies to address multiple disease drivers simultaneously, enabling broader therapeutic impact and improving long-term patient outcomes
10:00 am Leveraging an Energy Expenditure Mechanism to Drive Liver-Targeted Reductions in Fat and Inflammation, the Primary Drivers of MASH
- Leveraging a mitochondrial uncoupling approach to increase resting energy expenditure, resulting in muscle-preserving reductions in fat, particularly visceral fat, while independently reducing inflammation.
- Utilizing a liver-targeted therapy to reduce liver fat and inflammation, the primary drivers of MASH, while preserving muscle, which is critical for sustained cardiometabolic health.
- Developing oral small molecule therapies with favorable tolerability profiles to address chronic metabolic dysfunction, improving long-term patient management, and supporting sustained cardiometabolic health.
10:30 am Morning Break & Networking
Advancing Cirrhosis & Late-Stage Mash Treatments To Address High-Risk Populations, Expand Treatment Opportunities & Improve Clinical Outcomes
11:30 am Demonstrating Fibrosis Regression Through Non-Invasive Assessments in the Ph2b SYMMETRY Trial of Efruxifermin: Advancing Development in Compensated Cirrhosis Due to MASH
- Evaluating changes in multiple non-invasive tests to assess fibrosis regression and disease improvement, enabling more comprehensive treatment monitoring and supporting development in advanced MASH populations
- Leveraging longitudinal non-invasive assessment approaches to characterize therapeutic impact over time, improving understanding of disease modification and strengthening clinical decision-making
- Generating evidence of improvement across measures associated with advanced liver disease to support development strategies, enabling greater confidence in therapeutic benefit and improving future patient outcomes
12:00 pm Targeting Cirrhosis & Fibrotic Complications To Improve Translational Relevance, Enable Late-Stage Intervention & Expand Therapeutic Impact In Mash
- Targeting cirrhotic progression and fibrotic complications to improve translational understanding of advanced disease, enabling more clinically relevant therapeutic development
- Developing preclinical strategies focused on cirrhosis-associated pathways to improve intervention opportunities, strengthening late-stage treatment potential and translational applicability
- Expanding therapeutic focus beyond early fibrosis to address advanced MASH populations, improving long-term clinical impact and future treatment opportunities
12:30 pm Lunch & Networking
Implementing Precision Medicine, Preclinical & Clinical Strategies To Improve Treatment Options & Maximize Patient Benefit
1:30 pm Identifying High-Risk Patient Populations Through Clinical & Biomarker Insights to Enable Earlier Intervention & Improve Long-Term Outcomes in MASH
- Integrating clinical, imaging, and multi-omics biomarkers to improve identification of high-risk MASH patients and enable earlier intervention
- Understanding disease progression trajectories across heterogeneous patient populations, including metabolic comorbidities and fibrosis risk
- Leveraging translational biomarkers to bridge preclinical findings with clinical outcomes and improve decision-making in drug development
- Applying risk stratification strategies to optimize patient selection, monitoring, and therapeutic timing in clinical trials and real-world settings
2:00 pm Neuro-Immuno-Metabolic Regulation of MASH Progression
- Investigating immune-mediated mechanisms underlying MASH progression to identify novel therapeutic intervention opportunities, enabling more targeted treatment strategies and improving disease modification potential
- Evaluating emerging immunomodulatory approaches in preclinical models to influence key pathways associated with inflammation and fibrosis, strengthening mechanistic understanding and expanding future therapeutic possibilities
- Leveraging preclinical insights to support the development of precision medicine strategies that address diverse disease drivers, improving translational relevance and maximizing long-term patient benefit
2:30 pm Afternoon Break & Networking
3:00 pm Targeting Bile Salt Hydrolase with the Oral Small Molecule VT-6382 as a Novel and Differentiated Approach to Treating MASH and Liver Fibrosis
- Bile acid homeostasis is dysregulated in MASH and liver fibrosis, with progressive increases in secondary bile acids occurring across the MAFLD-MASH-fibrosis continuum. Targeting bile salt hyrdrolase (BSH), an essential nodal enzyme in bile acid regulation, has the potential to restore bile acid homeostasis and associated signaling.
- VT-6382 is an orally administered, gut-restricted small molecule inhibitor of BSH
- Chronic administration of VT-6382 to hyperphagic mice in the foz/foz model of progressive MASH and liver fibrosis lead to significant, dose-dependent improvements in several key MASH- and fibrosis-related endpoints as well as significant appetite suppression and weight loss. VT-6382 is being developed as a promising new approach to management of cardiometabolic disease.
3:30 pm Panel Discussion: Defining The Future Mash Treatment Landscape To Prioritize Differentiated Therapies, Optimize Combination Strategies & Establish Long-Term Standards Of Care
- Defining future standards of care across fibrosis, metabolic dysfunction and advanced disease populations to prioritize differentiated therapies, improving long-term clinical and commercial positioning
- Evaluating how combination strategies and emerging mechanisms will shape the post-Rezdiffra treatment landscape to optimize development planning, enabling stronger therapeutic differentiation and improved patient outcomes
- Identifying the clinical, regulatory and competitive factors that will determine best-in-class therapies to strengthen late-stage development strategies, improving adoption potential and long-term market success